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Abstract
Potassium is the major intracellular cation in the human body. Over 98% of the total 
body potassium is located within the intracellular compartment. In healthy adults, the 
total intracellular content of potassium is equivalent to 3000–3500 mmol. Approximately 
70% of this amount is found in skeletal muscle with lesser amounts in bone, red blood 
cells, liver and skin. The extracellular compartment contains 1–2% of the total body 
potassium. This uneven distribution of total body potassium is the result of an electro-
genic pump, Na+, K+ ATPase. This pump transports three sodium ions extracellularly 
in exchange of transporting two potassium ions intracellularly. This mechanism cre-
ates a ratio that determines the cell membrane potential. Maintenance of this potas-
sium ratio and membrane potential is vital for normal nerve conduction and muscular  
contraction.
Keywords: hyperkalemia, hypokalemia, acidosis, alkalosis
1. Potassium physiology and homeostasis
The kidney is responsible for maintaining the total body potassium content by matching 
intake with excretion. Insulin and catecholamines are primarily responsible for the regulation 
and distribution of potassium between the intracellular and extracellular compartments [21].
Other factors that can alter the distribution of potassium between compartments include acid-
base disorders, plasma osmolarity and exercise. The following section describes the effects of 
these factors in causing transcellular shifts of potassium.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1.1. Transcellular shifts
1.1.1. Insulin and catecholamines
After a meal, postprandial release of insulin shifts dietary potassium from the extracellular 
compartment into the intracellular compartment. This trans-cellular shift is mediated by insu-
lin binding to cell surface receptors, which stimulates glucose uptake in insulin-responsive 
tissues via the glucose transporter protein, GLUT 4.
Furthermore, insulin activates the Na+, K+ ATPase pump via increased intracellular CAMP 
production. This increases cellular uptake of potassium, thereby lowering serum potassium. 
In contrast to insulin, the effect of potassium regulation by catecholamines is dependent on 
which adrenergic receptor subtype is activated.
Activation of the beta 2 receptor triggers Na+, K+ ATPase, which induces cellular potassium 
uptake causing a fall in serum potassium. Activation of the alpha 1 receptor has the opposite 
effect, causing inhibition of Na+, K+ ATPase preventing cellular uptake and causing elevated 
serum potassium levels. These effects have important pharmacological implications. Drugs 
that block beta 2 receptors tend to increase serum potassium. Likewise, drugs that block the 
alpha 1 receptors can lower serum potassium.
1.1.2. Aldosterone
Aldosterone alters the distribution of potassium between the extracellular and intracellular 
compartments. The Na+, K+ ATPase pump is activated by aldosterone and causes cellular uptake 
of potassium. In the absence of altered renal potassium excretion, hypokalemia can result.
Aldosterone can also increase potassium excretion via the kidneys and to some degree by the 
gastrointestinal tract.
Details on the actions of aldosterone in the renal tubule are further explained in Section 1.5.
1.1.3. Hyperglycemia/hyperosmolality
Hyperglycemia and hyperosmolarity cause water movements from the intracellular to the 
extracellular compartment. This movement is responsible for solvent drag which transports 
potassium out of the cell. Additionally, cell shrinkage occurs and increases intracellular potas-
sium concentration. There is feedback inhibition of the Na/K ATPase pump which decreases 
cellular uptake of potassium, thus normalising intracellular potassium. This creates a concen-
tration gradient that allows for potassium exchange between compartments.
1.1.4. Metabolic acidosis
Metabolic acidosis is associated with abnormal serum potassium. Acidosis caused by inorganic 
anions such as NH
4
Cl and HCl can result in hyperkalemia. The mechanism behind this is not 
understood. Organic acids such as lactic acid generally do not cause potassium shifts between 
compartments. Hyperkalemia may be seen in lactic acidosis; this is the result of tissue ischemia 
causing cellular death and release of intracellular potassium into the extracellular fluid.
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1.1.5. Exercise
Exercise has multiple effects on potassium. Contraction of skeletal muscle during heavy 
exercise results in release of potassium. This in turn signals catecholamine release which 
stimulates alpha 1 adrenergic receptors to cause potassium to shift out of cells. The increase in 
extracellular potassium further induces arterial vasodilation in normal blood vessels, thereby 
increasing skeletal blood flow. Catecholamine release during exercise also activates beta 2 
adrenoreceptors which increase skeletal muscle uptake of potassium, regulating potassium 
and minimising exercise-induced hyperkalemia.
1.2. Dietary intake
According to international dietary guidelines, the recommended dietary intake of potassium 
should be 90–120 mmol/day [3, 20].
Potassium is absorbed through the gastrointestinal tract and is distributed amongst the intra-
cellular and extracellular fluid compartments. Dietary intake varies worldwide; the western 
diet provides 50–100 mmol of potassium daily [3, 21].
Foods that are rich in potassium include many fruits and vegetables.
After a potassium-rich meal, increases in extracellular potassium are negated by rapid cel-
lular uptake that allows for elimination in the urine over a period of 6–8 h.
About 90% of potassium is excreted in the urine with the remaining 10% excreted via the 
stool.
Potassium homeostasis is controlled by the changes in renal potassium excretion. The follow-
ing section describes the basic physiology of renal potassium excretion.
1.3. Renal potassium excretion
Evolving concepts in renal potassium excretion involves the recognition of reactive and pre-
dictive systems [16].
The reactive system comprises of a negative and a forward system. The negative system 
consists of a negative feedback loop that modulates renal potassium, on the basis of plasma 
potassium and serum aldosterone levels [16].
High plasma potassium concentrations or elevated serum aldosterone levels increase urinary 
potassium excretion bringing plasma potassium concentration back to physiologic range. 
The forward system describes an unidentified potassium-sensing gut factor that increases 
urinary potassium excretion, in response to a high potassium diet before an increase in 
plasma potassium concentration, or changes in plasma aldosterone levels occur [4, 5, 7]. In 
addition to these systems, a circadian rhythm of potassium excretion has been proposed, 
for instance, the predictive system which is independent of potassium intake and activity. 
In studies measuring urinary potassium excretion, it has been observed that urinary potas-
sium excretion is the lowest in the night and early mornings and highest from noon to early 
afternoon [16].
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1.4. Renal potassium handling
Serum potassium is almost completely ionised and not bound to plasma proteins. It is filtered 
through the glomerulus. Approximately 65–70% of potassium filtered through glomeruli is 
reabsorbed in the proximal tubule. Less than 10% of the filtered load reaches the distal nephron.
Potassium reabsorption in the proximal tubule primarily occurs through paracellular pathways.
Sodium reabsorption across the tubule allows for fluid absorption to occur. As a result of this pro-
cess, solvent drag occurs which permits potassium reabsorption. In addition, the electrical volt-
age within the tubular lumen gradually becomes more positive as fluid flows down the tubule.
This change in voltage provides an additional force favouring potassium reabsorption 
through the paracellular pathway, which is of low resistance.
In the loop of Henle, both secretion and absorption occur. Potassium is secreted in the 
descending loop in deep nephrons and is reabsorbed in the ascending loop through the action 
of the Na+, K+ 2Cl− cotransporter. The majority of the potassium reabsorbed by this protein 
is recycled back into the tubular lumen by the renal outer medullary potassium channel 
(ROMK), an ATP-dependent apical potassium channel that transports potassium out of cells. 
Modest net absorption of potassium occurs as a result of this process. The site and regulation 
of renal potassium excretion predominantly occurs in the distal tubule and collecting duct.
The distal nephron, which comprises the distal tubule and collecting duct, has both reabsorp-
tive and secretory functions. Potassium excretion primarily occurs here.
There are several cell types within the epithelium of the distal tubule and collecting ducts. The 
most important of these cell types are the principal cells, which approximate to 70% of cells 
and the intercalated cells. Both cell types are located within the collecting duct. Principal cells 
are primarily located within the cortical collecting duct and intercalated cells are dispersed 
throughout the entire length of the collecting duct.
Potassium secretion is by principal cells, which involves uptake of potassium from the inter-
stitium by Na+, K+ ATPase and secretion into the tubular lumen through potassium channels: 
ROMK and BK also known as maxi-K.
ROMK and BK are both permeable to potassium and are regulated by different mechanisms [3].
There are several factors that influence principal cells to secrete potassium. These factors 
include low potassium diet, high potassium diet, angiotensin II, high serum potassium, aldo-
sterone, luminal flow rate, extracellular pH and high Na delivery.
Sodium delivery to the distal tubule is the major regulator of potassium excretion. High 
sodium delivery stimulates potassium secretion. It achieves this in two ways. Firstly, 
increased sodium delivery causes increased sodium entry via epithelial sodium channels 
(ENaC), which depolarises the apical membrane causing an increase in the electrochemical 
gradient, promoting outward flow potassium through the potassium channels. Secondly, the 
more sodium delivered to the tubule, the more sodium is pumped out by Na+, K+ ATPase and 
more potassium is pumped in [3].
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This potassium is then secreted across the apical membrane of principal cells into the luminal 
fluid by apical potassium channels.
At low dietary loads of potassium, there is no secretion by either channel. The body is con-
serving potassium. ROMK channels are sequestered into intracellular vesicles. BK channels 
are closed [3]. In normal concentrations of potassium, ROMK channels secrete potassium 
whereas BK channels remain closed. In conditions where there is high potassium secretion, 
for example, high potassium diet, both ROMK and BK channels are open [3].
Angiotensin II is an inhibitor of potassium secretion; its mode of action is to decrease activity 
of ROMK, thereby limiting potassium flux into the tubular lumen.
The intercalated cells are subdivided into type A which are numerous, type B which are lim-
ited in number and non-A and non-B cells.
The intercalated cells, particularly type A, reabsorb potassium. Type A intercalated cells reab-
sorb potassium via the H+, K+ ATPase, located within the apical membrane which actively 
takes up potassium from the lumen in exchange for hydrogen ions. Potassium can then enter 
the tubular interstitium across the basolateral membrane via potassium channels. In condi-
tions of low potassium, potassium depletion increases H+, K+ ATpase expression resulting in 
increased active potassium reabsorption and decreased potassium excretion.
An important regulator of potassium in the distal nephron is the enzyme with no lysine 
kinases (WNK kinases). WNK kinases activate sodium reabsorption in the distal tubule and 
inhibit the ROMK channel [16, 22].
As a result of this, there is decreased sodium delivery to the collecting duct, and coupled with 
this is decreased ROMK expression leading to decreased potassium secretion [16, 22].
WNK kinase activity is sensitive to chloride and potassium concentrations [16, 22].
1.5. Aldosterone paradox
Aldosterone has the ability to signal the kidney to cause sodium retention without potassium 
secretion in states of volume depletion but can also stimulate potassium secretion without 
sodium retention in the hyperkalemic state [6].
In humans, aldosterone is the major mineralocorticoid. It promotes sodium absorption and 
potassium excretion by binding to mineralocorticoid receptors located in the distal tubules 
and collecting ducts. Aldosterone increases Na+, K+ ATPase activity in the basolateral mem-
brane which is responsible for sodium reabsorption across the luminal membrane. This 
increases the electronegativity of the lumen which increases the electrical gradient and potas-
sium permeability.
In states of volume depletion, the renin-angiotensin-aldosterone axis is activated and causes 
renal sodium absorption restoring extracellular fluid volume without a demonstrable effect on 
renal potassium excretion. In the presence of hyperkalemia, release of aldosterone increases 
urinary potassium excretion, thereby restoring serum potassium levels to normal. This effect, 
however, does not result in sodium renal retention.
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2. Disorders of potassium
2.1. Hypokalemia
2.1.1. Epidemiology
Hypokalemia is defined as serum potassium concentration levels of <3.5 mmol and is a com-
mon electrolyte disturbance amongst hospitalised patients [6].
As many as 20% of hospitalised patients are found to have hypokalemia, but only 4–5% of this 
is deemed to be clinically significant [6, 13, 22].
There are no significant differences in its prevalence amongst males and females [6].
2.1.2. Aetiology
2.1.2.1. Redistribution
About 2% of the total body potassium is within the extracellular compartment. Consequently, 
small shifts of potassium from the extracellular compartment to the intracellular compart-
ment can cause hypokalemia. Additionally, glycogenesis during total parenteral nutri-
tion or enteral hyperalimentation causes insulin release which shifts potassium into cells. 
Furthermore, the sympathetic nervous system is involved in the activation of the beta 2 recep-
tors causing intracellular shift of potassium. Stimulation of beta 2 receptors can also occur in 
thyrotoxicosis.
A rare cause of redistribution-induced hypokalemia is hypokalemic periodic paralysis. In this 
condition, flaccid paralysis and muscular weakness occur during the night or early mornings, 
typically after ingestion of a large carbohydrate meal.
2.1.2.2. Renal potassium losses
Renal potassium losses are the most common cause of hypokalemia.
Drugs are common causes of renal potassium loss.
Thiazide and loop diuretics block sodium reabsorption in the distal convoluted tubule and 
loop of Henle, respectively. Reabsorption does not occur proximal to the collecting duct, 
thereby increasing sodium delivery to the principal cells of the collecting duct. This stimulates 
sodium uptake and at the same time promotes potassium secretion causing potassium loss 
resulting in hypokalemia.
High dosage of penicillins is thought to cause hypokalemia by increased sodium delivery to 
the collecting duct and principal cells which result in urinary potassium secretion [22].
The antifungal agent amphotericin directly increases collecting duct secretion of potassium. 
This is achieved by its direct action of binding to collecting duct cells and forming pores 
which result in potassium loss.
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The mechanism of action for aminoglycosides causing hypokalemia is not completely under-
stood [22]. It is postulated that ROMK is activated by aminoglycosides causing urinary potas-
sium secretion [22].
Cisplatin, an antineoplastic agent can cause both hypokalemia and hypomagnesemia.
Hypokalemia is related to hypomagnesemia. Magnesium mediates inhibition of ROMK. In 
states that where there is magnesium deficiency, ROMK inhibition is lost enabling potassium 
excretion [22].
Coupled with this is inhibition of Na+, K+ ATPase pump caused by low magnesium, causing 
potassium to be excreted via K channels particularly in the thick ascending limb [22].
Toluene is thought to lead to potassium wasting by causing renal tubular acidosis (RTA) [22].
Licorice and herbal cough mixtures contain glycyrrhizic and glycyrrhetinic acids. They are 
thought to exert mineralocorticoid effects leading to hypokalemia [22].
Bicarbonaturia results from metabolic alkalosis, distal RTA or treatment with proximal RTA.
Increased distal tubular bicarbonate delivery increases potassium secretion.
Magnesium deficiency can cause high potassium excretion and potassium deficiency. Under 
ideal conditions, intracellular magnesium inhibits the apical ROMK channel. In magnesium 
deficiency, the ROMK channel is not inhibited by magnesium resulting in increased potas-
sium excretion.
Magnesium deficiency should be suspected when potassium replacement does not correct 
the hypokalemia.
Intrinsic renal potassium transport defects are rare. Barterrs, Gittlemanns and Liddles are 
such conditions. A review of these conditions is not described here.
Similarly, detailed descriptions of genetic defects that result in elevated levels of aldosterone, 
glucocorticoid remediable aldosteronism, congenital adrenal hyperplasia and syndrome of 
apparent mineralocorticoid excess, are not described in great detail here (See Table 1).









• Herbal cough mixtures






• Syndrome of apparent mineralocorti-
coid excess
• Congenital adrenal hyperplasia
Table 1. Causes of renal potassium losses.
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2.1.2.3. Extra-renal potassium losses
The skin and gastrointestinal tract excrete small amounts of potassium. Excessive sweat-
ing or chronic diarrhoea can cause potassium losses. Likewise, vomiting or nasogastric 
suction can cause hypokalemia although gastric fluids contain only 5–8 mmol/l of potas-
sium. This is associated with concomitant metabolic alkalosis and intravascular volume 
depletion which cause secondary hyperaldosteronism and increases urinary potassium 
loss.
2.1.2.4. Pseudohypokalemia
Pseudohypokalemia occurs when serum potassium decreases artifactually after phlebotomy.
Acute leukemia is the most common cause. Abnormal leucocytes take up potassium when 
blood is stored in collection vial for a prolonged period of time at room temperature. Rapid 
separation of plasma and storage at 4°C are used for diagnosis.
Clinical features: the clinical manifestations of hypokalemia are proportionate to the degree 
and duration of serum potassium reduction.
Symptoms are often not present until serum potassium is below 3.0 mmol/L.
A potentiating factor such as digoxin can predispose hypokalemic patients to have cardiac 
arrhythmias because of altered resting membrane potential.
2.1.2.5. Cardiac
Epidemiological studies have linked hypokalemia and low potassium diet with an increased 
prevalence of hypertension.
Potassium deficiency can increase blood pressure. Mechanisms that have been proposed to be 
responsible for this effect include sodium retention with subsequent increased intravascular 
volume and endogenous vasoconstriction which sensitises the vasculature.
Electrocardiographic (ECG) changes with cardiac arrhythmias can be seen. Common ECG 
changes are U waves and ST segment depression along with T wave flattening.
2.1.2.6. Hormonal
Hypokalemia impairs insulin release and induces insulin resistance which worsens glycemic 
control in diabetic patients.
2.1.2.7. Muscular
Hypokalemia can lead to skeletal muscle weakness and increases sensitivity to develop exer-
tional rhabdomyolysis by reducing skeletal muscle blood flow. Furthermore, hypokalemia 
hyperpolarises skeletal muscle reducing muscle contraction.
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2.1.2.8. Renal
Hypokalemia can lead to significant disturbances in renal function.
Reduced medullary blood flow and increased renal vascular resistance may result in hyper-
tension, tubulointerstitial and cystic changes, acid base disturbances and damage to the renal 
concentrating mechanisms [22].
Potassium deficiency can cause tubulointerstitial fibrosis which is seen in the outer medulla. 
The duration of hypokalemia determines the degree of damage. Prolonged hypokalemia 
may result in renal failure. Furthermore, chronic potassium deficiency causes renal hyper-
trophy that can lead to renal cyst formation particularly during increased mineralocorti-
coid use [22].
Hypokalemia increases renal ammonia production.
Metabolic alkalosis is associated with hypokalemia and occurs because of increased renal net 
acid secretion as a result of increased ammonia excretion [22].
Additionally, it can also cause increased urinary potassium secretion resulting in hypokalemia.
In cases of severe hypokalemia, respiratory muscle weakness may arise leading to the devel-
opment of respiratory acidosis and if severe, respiratory acidosis.
Severe potassium depletion can cause polyuria, with urinary outputs measuring 2–3 L.
Increased thirst and nephrogenic diabetes insipidus are factors potentiating the severity of 
polyuria. Nephrogenic diabetes insipidus is a result of decreased expression of water trans-
porter aquaporin 2 (AQP2) and urea transporter proteins UT-A1, UT-A3, and UT-B which 
take part in urine concentration mechanisms and water reabsorption [22].
2.1.2.9. Nervous system
Cramps, paresthesias, paresis, and ascending paralysis are typical features of neurological 
involvement.
2.1.2.10. Treatment
Treatment approach is dependent on the severity of hypokalemia and the presence of 
symptoms. Treatment should include reducing the amount of potassium lost, replenishing 
potassium stores, assessing for potential toxicities, and determining the cause so that future 
episodes can be prevented [6, 22].
Short-term risks of hypokalemia are cardiovascular arrhythmias and neuromuscular weak-
ness which can be life-threatening and require urgent treatment in the form of intravenous 
potassium usually 5–10 mmol over 15–20 min [22].
Urgent treatment for hypokalemia however is rarely required [14].
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It should be noted that the body responds to potassium losses, by shifting potassium 
from the ICF compartment to the ECF compartment, minimising change in extra-cellular 
potassium. With potassium replacement, potassium is shifted back into the ICF. The 
degree or magnitude of potassium deficiency can be masked. The amount of potassium 
required to replace the potassium lost is greater than predicted change in extra-cellular 
volume [6, 22].
The severity of hypokalemia determines the administration of either intravenous or oral 
potassium. Patients presenting with potassium levels of 2.5–3.5 mmol represent mild 
to moderate hypokalemia and can be treated with oral potassium supplements. Severe 
hypokalemia defined as potassium levels of <2.5 mmol should be treated with intravenous 
potassium [6, 22].
Hypokalemia is associated with magnesium deficiency. Magnesium is important for potas-
sium uptake and for maintenance of intracellular potassium levels particularly in the myo-
cardium [1].
2.1.2.11. Intravenous potassium
Intravenous potassium infusions can cause pain if given peripherally via a small vein. The 
maximum rate of potassium administration peripherally is 10 mmol/h [1, 6, 22].
In cases where more rapid replacement is necessary, potassium infusion rates >10 mmol/h 
can be administered but require central access, electrocardiograph monitoring and frequent 
monitoring of serum potassium [1, 6, 22].
2.1.2.12. Oral potassium
Oral potassium supplements can take the form of potassium chloride or effervescent tablets.
Potassium chloride tablets contain 8 mmol of potassium per tablet, as opposed to effervescent 
tablets which contain 14 mmol per tablet (Table 2).
2.2. Hyperkalemia
2.2.1. Epidemiology
Hyperkalemia occurs frequently amongst patients with chronic kidney disease, diabetes and 
heart failure and patients using RAAS inhibitors (renin-angiotensin-aldosterone) or NSAIDS 
(non-steroidal anti-inflammatories). Less than 1% of normal healthy adults develop hyperka-
lemia [22].
2.2.2. Aetiology
Hyperkalemia can be the result of psuedohyperkalemia, potassium redistribution from intra-
cellular fluid to extracellular fluid and imbalances between potassium intake and excretion.
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In this section, a brief description of each cause is given.
2.2.3. Psuedohyperkalemia
Release of potassium from erythrocytes after phlebotomy occurs. Free hemoglobin is released 
into plasma from damaged erythrocytes and is reported as hemolysis. In the presence of 
hemolysis, reported plasma potassium is not representative of the actual plasma potassium. 
Treatment should not be initiated, and repeat measurement of plasma potassium must take 
place.
Ischemia from difficult phlebotomy or exercise of limb in the presence of tourniquet can lead 
to abnormally increased potassium values. Potassium can also be released from other cellular 
elements present in blood during clotting particularly, with severe leucocytosis (>70,000/cm3) 
or thrombocytosis. About one-third of patients with platelet counts of 500–1000 × 10−9 have 
psuedohyperkalemia [22].
Diagnosis of psuedohyperkalemia is made by measuring serum/plasma potassium.
2.2.3.1. Redistribution
Hyperglycemia from insulin deficiency and hyperosmolarity are important causes of potas-
sium movement from the intracellular fluid to the extracellular fluid. Moreover, medications 
such as beta 2 adrenoreceptor antagonists, RAAS inhibitors and mineralocorticoid receptor 
blockers are common agents that can cause hyperkalemia.
2.2.3.2. Potassium intake
In general, excessive dietary intake does not cause chronic hyperkalemia because the kidney 
can excrete ingested potassium.
There are other factors that contribute to hyperkalemia when renal potassium excretion is 
impaired.
Hypokalemia Treatment
Mild (3.0–4.0 mmol) Oral potassium:
• Effervescent tablets1–2 tabs bd (14–28 mmol)
• Potassium chloride tablets 1–2 tabs bd (8–16 mmol)
• IV potassium; 60 mmol/24 h
Moderate (2.5–3.0 mmol) Oral requirements; total requirements are 96 mmol/day [2].
IV potassium infusion; 90 mmol/24 h [2]
Severe (<2.5 mmol) IV potassium infusion: 5–10 mmol/h
Table 2. Treatment of hypokalemia.
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2.2.3.3. Impaired potassium excretion
In patients with decreased kidney function, there is impaired potassium excretion.
In chronic kidney disease, renal potassium secretion from distal nephrons is preserved until 
the glomerular filtration rate is reduced to 10–20 ml/min [22].
Medications can affect potassium excretion. A list of medications and their effects is described 
in Table 3.
Hyperkalemia may occur in obstructive uropathy. This is in part due to decreased Na+, K+ 
ATpase expression and activity. It can persist for months or years after the obstruction is 
relieved [22].
This is thought to be due to a persistent defect in the collecting duct, where secretion is impaired.
Aldosterone deficiency is not responsible.
Class Class example Mechanism
Potassium-containing 
drugs
Potassium chloride Increased potassium intake
Beta adrenergic blockers Propranolol, metoprolol, and atenolol Inhibition of renin release
Angiotensin-converting 
enzyme (ACE) inhibitors




Irbesartan, losartan, and candesartan Inhibition of angiotensin I receptor by 
angiotensin II
Direct renin inhibitors Aliskiren Inhibition of renin activity resulting in 
decreased angiotensin II production
Heparin Heparin sodium Inhibition of aldosterone synthase, rate-
limiting enzyme for aldosterone synthesis
Aldosterone receptor 
antagonists
Spironolactone and eplerenone Block aldosterone receptor activation
Potassium-sparing 
diuretics
Amiloride and triamterene Block collecting duct apical ENaC 
channel, decreasing gradient for K 
secretion.
NSAIDS and COX-2 
inhibitors
Ibuprofen Inhibition of prostaglandin stimulation 
of collecting duct potassium secretion. 
Inhibition of renin release
Digitalis glycosides Inhibition of Na+, K+ ATPase necessary for 
collecting duct K secretion and regulation of 
K distribution into cells.
Digoxin
Calcineurin inhibitors Inhibition of Na+, K+ ATPase necessary for 
collecting duct K secretion.
Cyclosporine and tacrolimus
Table 3. Pharmacological agents causing hyperkalemia. Class Example and Action description for digoxin and CNI need 
to be reversed, for eg action of drug for digoxin under class example and class example digoxin is under action of drug, 
this also applies FOR CNI.
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2.3. Clinical manifestations
Hyperkalemia may be asymptomatic or cause life threatening arrhythmias.
2.3.1. Cardiac
Hyperkalemia decreases the transmembrane potassium gradient. This results in cell mem-
brane depolarisation, slowing of ventricular conduction and decrease in the duration of the 
action potential. These changes result in electrocardiogram (ECG) manifestations including 
peaked T waves, broadening of QRS complexes, loss of p wave and ventricular fibrillation 
which can lead to asystole. Changes in plasma potassium may not result in ECG changes. 
ECG has been described to be a poor tool for detecting hyperkalemia with a sensitivity of 
34–40% [9–12, 15].
2.3.2. Neuromuscular
Neuromuscular effects include paresthesias, weakness and paralysis. Deep tendon reflexes 
may be depressed or absent. Sensory findings are absent.
2.3.3. Gastrointestinal
Nausea, vomiting and diarrhoea can occur but are less encountered.
2.4. Diagnosis
Transtubular potassium gradient (TTKG) can help distinguish renal causes of hyperkalemia 
from non-renal causes.
It is a measurement of net potassium secretion by the collecting duct after correcting for 
changes in urinary osmolality.
The formula is as follows Eq. (1):
  TTKG =  
urine potassium ⋅ urine osmolality
   ______________________________________ 
plasma potassium ⋅ plasma osmolality (1)
2.4.1. Effects on the cardiac system
Calcium given by the parenteral route does not produce changes in extracellular potassium 
but stabilises cell membrane potential by ameliorating the effects of hyperkalemia on myocar-
dial conduction system and depolarisation [22] (Tables 4 and 5).
Responses occur within a few minutes and duration of action is between 30 and 60 min.
Although there are no clinical studies assessing efficacy, it has been accepted for the treatment of 
hyperkalemia when life threatening ECG changes are present or when cardiac arrest occurs. Life-
threatening ECG changes include absent P waves, broad QRS complexes and sine-wave pattern.
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The dose of calcium gluconate is higher than calcium chloride because it requires liver metab-
olism to release calcium.
2.4.2. Cellular uptake of potassium
Insulin and beta 2 adrenergic agonists stimulate cellular uptake of potassium. Insulin achieves 
this by binding to insulin receptors located on skeletal muscle. The duration of action for insu-
lin can last for 4–6 h. Glucose is co-administered to prevent hypoglycemia.
Beta 2 receptor adrenergic agonists can be administered via inhalation and subcutaneous or 
intravenous routes. Tachycardia is a significant complication of therapy particularly at high 
doses required to treat hyperkalemia (2–8 times higher given for bronchodilation).
TTKG Indication
<5–7 Suggest aldosterone deficiency or resistance
6–12 Normal
>10 Suggest normal aldosterone action and extra renal cause of increased potassium.
Table from Comprehensive Clinical Nephrology 6th Edition. 2019.
Table 4. Interpretation of TTKG.











Intravenous 1–3 min Cell membrane stabilisation
Insulin with dextrose 10 units IV with 
50 mls of 50% 
dextrose
Intravenous 30 min Cellular potassium uptake
Beta 2 adrenergic 
agonist
Salbutamol 15–20 mg Nebuliser 30 min Cellular potassium uptake
Sodium polystyrene 
sulfonate
30 g–60 g Oral >2 h Potassium removal by potassium 
binding resins






Transcellular shift by 
alkalinisation
Bicarbonate affecting H/K 
exchange; pushes potassium back 
into cells.
*Sodium bicarbonate can be considered if acidemia is present; pH <7.2.
++Hemodialysis is the most effective method of removal of potassium. Acute hemodialysis is indicated when hyperkalemia 
is life threatening and is refractory to medical treatment. The more severe the hyperkalemia is, the more rapid reduction 
of plasma potassium is required, until serum potassium is <6.0 mmol/L.
Table 5. Treatment of hyperkalemia.
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It has been reported that upto 25% of patients with hyperkalemia do not respond to beta 2 
agonist therapy [17, 19].
2.4.3. Potassium removal
Reducing total body potassium involves decreased oral intake, enhanced fecal and urinary 
potassium excretion and dialysis.
In terms of dietary intake, limited amounts of citrus fruits, potatoes, tomatoes and salt prod-
ucts should be ingested.
Hemodialysis is the most effective mode of removal of potassium. In patients with advanced 
renal failure, the ability of the distal nephron to excrete potassium is reduced. In these patients, 
hemodialysis is the preferred mode of removal.
Oral potassium binding resins are other agents used in the treatment of hyperkalemia.
This is best observed in patients with chronic hyperkalemia. Sodium polystyrene sul-
fonate and calcium polystyrene sulfonate are common agents used. They exchange 
sodium and calcium, respectively, for potassium in the gastrointestinal tract. It can be 
administered orally or rectally as a retention enema. Furthermore, polystyrene sulfo-
nates have been reported to cause constipation, intestinal necrosis and colonic perfora-
tion. Consequently, newer agents have been developed and are being evaluated in clinic 
trials.
Sodium zirconium cyclosilicate (ZS-9) is an oral cation exchanger designed to trap monovalent 
cations in the gastrointestinal tract. Its framework structure is full of micropores that allow 
selectivity of trapping potassium ions in exchange for sodium and hydrogen. Clinical trials 
have demonstrated its success in lowering plasma potassium levels within 24 h. The onset 
of action is 1 h following the first dose. Dose has varied from 2.5 to 10 g. Dose-dependent 
oedema is a notable side effect. It should be given 2 h apart from oral medications with gastric 
pH dependence. It binds potassium throughout the gastrointestinal tract. The bioavailability 
is 7 h after the onset of action after the first dose. Location of potassium binding is predomi-
nantly in the distal colon.
Long-term effects on mortality are still yet to be confirmed. In May 2018, the FDA approved 
ZS-9 for the treatment of hyperkalemia. It is known as Lokelma in the USA.
Patiromer is another new agent that binds potassium in the lumen of the gastrointestinal tract.
It consists of a polymer anion (the active moiety patiromer) and a calcium-sorbitol complex.
Clinical trials have shown a reduction in plasma potassium levels but there are some side 
effects that have been observed. Hypomagnesemia has been reported in patients taking this 
agent.
Its use in patients with cardiac arrhythmia has been questioned, as hypomagnesemia can 
be associated with cardiac arrhythmias. It can also cause gastrointestinal side effects, for 
example, mild to moderate constipation. Its brand name is Veltessa.
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